PMC:7247521 / 29019-31631 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"418","span":{"begin":1071,"end":1075},"obj":"Gene"},{"id":"419","span":{"begin":1140,"end":1144},"obj":"Gene"},{"id":"420","span":{"begin":1212,"end":1220},"obj":"Gene"},{"id":"421","span":{"begin":1281,"end":1289},"obj":"Gene"},{"id":"423","span":{"begin":867,"end":876},"obj":"Species"},{"id":"425","span":{"begin":1809,"end":1812},"obj":"Disease"},{"id":"429","span":{"begin":2141,"end":2147},"obj":"Gene"},{"id":"430","span":{"begin":1931,"end":1943},"obj":"Disease"},{"id":"431","span":{"begin":2052,"end":2055},"obj":"Disease"},{"id":"433","span":{"begin":1899,"end":1907},"obj":"Disease"},{"id":"436","span":{"begin":2575,"end":2579},"obj":"Chemical"},{"id":"437","span":{"begin":2437,"end":2440},"obj":"Disease"},{"id":"446","span":{"begin":208,"end":223},"obj":"Gene"},{"id":"447","span":{"begin":286,"end":290},"obj":"Gene"},{"id":"448","span":{"begin":306,"end":310},"obj":"Gene"},{"id":"449","span":{"begin":329,"end":333},"obj":"Gene"},{"id":"450","span":{"begin":355,"end":363},"obj":"Gene"},{"id":"451","span":{"begin":382,"end":390},"obj":"Gene"},{"id":"452","span":{"begin":292,"end":297},"obj":"Gene"},{"id":"453","span":{"begin":19,"end":27},"obj":"Disease"}],"attributes":[{"id":"A418","pred":"tao:has_database_id","subj":"418","obj":"Gene:43740578"},{"id":"A419","pred":"tao:has_database_id","subj":"419","obj":"Gene:43740578"},{"id":"A420","pred":"tao:has_database_id","subj":"420","obj":"Gene:164045"},{"id":"A421","pred":"tao:has_database_id","subj":"421","obj":"Gene:164045"},{"id":"A423","pred":"tao:has_database_id","subj":"423","obj":"Tax:2697049"},{"id":"A429","pred":"tao:has_database_id","subj":"429","obj":"Gene:1185"},{"id":"A431","pred":"tao:has_database_id","subj":"431","obj":"MESH:D015473"},{"id":"A433","pred":"tao:has_database_id","subj":"433","obj":"MESH:C000657245"},{"id":"A437","pred":"tao:has_database_id","subj":"437","obj":"MESH:D015473"},{"id":"A447","pred":"tao:has_database_id","subj":"447","obj":"Gene:8673700"},{"id":"A448","pred":"tao:has_database_id","subj":"448","obj":"Gene:43740578"},{"id":"A449","pred":"tao:has_database_id","subj":"449","obj":"Gene:43740578"},{"id":"A450","pred":"tao:has_database_id","subj":"450","obj":"Gene:164045"},{"id":"A451","pred":"tao:has_database_id","subj":"451","obj":"Gene:164045"},{"id":"A452","pred":"tao:has_database_id","subj":"452","obj":"Gene:43740578"},{"id":"A453","pred":"tao:has_database_id","subj":"453","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T373","span":{"begin":19,"end":27},"obj":"SP_7"},{"id":"T374","span":{"begin":130,"end":139},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T375","span":{"begin":299,"end":304},"obj":"PR:000000125"},{"id":"T376","span":{"begin":322,"end":327},"obj":"PR:000000125"},{"id":"T377","span":{"begin":348,"end":353},"obj":"PR:000000125"},{"id":"T378","span":{"begin":364,"end":372},"obj":"SO:0000346"},{"id":"T379","span":{"begin":375,"end":380},"obj":"PR:000000125"},{"id":"T380","span":{"begin":402,"end":407},"obj":"PR:000000125"},{"id":"T381","span":{"begin":416,"end":421},"obj":"PR:000000125"},{"id":"T382","span":{"begin":434,"end":439},"obj":"PR:000000125"},{"id":"T383","span":{"begin":460,"end":465},"obj":"PR:000000125"},{"id":"T384","span":{"begin":480,"end":489},"obj":"PG_4"},{"id":"T385","span":{"begin":500,"end":509},"obj":"PG_2"},{"id":"T386","span":{"begin":511,"end":514},"obj":"CHEBI:24870;CHEBI:24870"},{"id":"T387","span":{"begin":686,"end":695},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T388","span":{"begin":738,"end":747},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T389","span":{"begin":793,"end":802},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T397","span":{"begin":867,"end":876},"obj":"SP_7"},{"id":"T398","span":{"begin":1899,"end":1907},"obj":"SP_7"},{"id":"T399","span":{"begin":2367,"end":2371},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T400","span":{"begin":2543,"end":2547},"obj":"CHEBI:23888;CHEBI:23888"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T95","span":{"begin":276,"end":284},"obj":"Body_part"},{"id":"T96","span":{"begin":316,"end":319},"obj":"Body_part"},{"id":"T97","span":{"begin":342,"end":345},"obj":"Body_part"},{"id":"T98","span":{"begin":409,"end":413},"obj":"Body_part"},{"id":"T99","span":{"begin":482,"end":489},"obj":"Body_part"},{"id":"T100","span":{"begin":502,"end":509},"obj":"Body_part"},{"id":"T101","span":{"begin":877,"end":885},"obj":"Body_part"},{"id":"T102","span":{"begin":1081,"end":1084},"obj":"Body_part"},{"id":"T103","span":{"begin":1153,"end":1156},"obj":"Body_part"},{"id":"T104","span":{"begin":1360,"end":1364},"obj":"Body_part"},{"id":"T105","span":{"begin":1644,"end":1651},"obj":"Body_part"},{"id":"T106","span":{"begin":1714,"end":1721},"obj":"Body_part"}],"attributes":[{"id":"A95","pred":"fma_id","subj":"T95","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A97","pred":"fma_id","subj":"T97","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A98","pred":"fma_id","subj":"T98","obj":"http://purl.org/sig/ont/fma/fma84120"},{"id":"A99","pred":"fma_id","subj":"T99","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A100","pred":"fma_id","subj":"T100","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A101","pred":"fma_id","subj":"T101","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma84120"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T60","span":{"begin":19,"end":27},"obj":"Disease"},{"id":"T61","span":{"begin":1899,"end":1907},"obj":"Disease"}],"attributes":[{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T247","span":{"begin":141,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T248","span":{"begin":204,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"},{"id":"T249","span":{"begin":229,"end":232},"obj":"http://purl.obolibrary.org/obo/CLO_0007875"},{"id":"T250","span":{"begin":229,"end":232},"obj":"http://purl.obolibrary.org/obo/CLO_0052410"},{"id":"T251","span":{"begin":902,"end":904},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T252","span":{"begin":905,"end":907},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"},{"id":"T253","span":{"begin":2141,"end":2144},"obj":"http://purl.obolibrary.org/obo/CLO_0002494"},{"id":"T254","span":{"begin":2265,"end":2268},"obj":"http://purl.obolibrary.org/obo/CLO_0002494"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T192","span":{"begin":4,"end":15},"obj":"Chemical"},{"id":"T193","span":{"begin":200,"end":202},"obj":"Chemical"},{"id":"T195","span":{"begin":204,"end":206},"obj":"Chemical"},{"id":"T196","span":{"begin":225,"end":227},"obj":"Chemical"},{"id":"T197","span":{"begin":276,"end":284},"obj":"Chemical"},{"id":"T198","span":{"begin":364,"end":367},"obj":"Chemical"},{"id":"T201","span":{"begin":482,"end":489},"obj":"Chemical"},{"id":"T202","span":{"begin":502,"end":509},"obj":"Chemical"},{"id":"T203","span":{"begin":511,"end":514},"obj":"Chemical"},{"id":"T204","span":{"begin":877,"end":885},"obj":"Chemical"},{"id":"T205","span":{"begin":896,"end":898},"obj":"Chemical"},{"id":"T207","span":{"begin":905,"end":907},"obj":"Chemical"},{"id":"T208","span":{"begin":927,"end":929},"obj":"Chemical"},{"id":"T209","span":{"begin":1221,"end":1224},"obj":"Chemical"},{"id":"T212","span":{"begin":1644,"end":1651},"obj":"Chemical"},{"id":"T213","span":{"begin":1714,"end":1721},"obj":"Chemical"},{"id":"T214","span":{"begin":1722,"end":1725},"obj":"Chemical"},{"id":"T215","span":{"begin":2367,"end":2371},"obj":"Chemical"},{"id":"T216","span":{"begin":2543,"end":2547},"obj":"Chemical"}],"attributes":[{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_51083"},{"id":"A194","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_53453"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"},{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_15379"},{"id":"A197","pred":"chebi_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_16761"},{"id":"A199","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_456216"},{"id":"A200","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_73342"},{"id":"A201","pred":"chebi_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A202","pred":"chebi_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_24870"},{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_51083"},{"id":"A206","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_53453"},{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"},{"id":"A208","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_15379"},{"id":"A209","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_16761"},{"id":"A210","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_456216"},{"id":"A211","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_73342"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_24870"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T100","span":{"begin":511,"end":522},"obj":"http://purl.obolibrary.org/obo/GO_0022831"},{"id":"T101","span":{"begin":1722,"end":1733},"obj":"http://purl.obolibrary.org/obo/GO_0022831"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-sentences","denotations":[{"id":"T216","span":{"begin":0,"end":525},"obj":"Sentence"},{"id":"T217","span":{"begin":526,"end":580},"obj":"Sentence"},{"id":"T218","span":{"begin":581,"end":725},"obj":"Sentence"},{"id":"T219","span":{"begin":726,"end":803},"obj":"Sentence"},{"id":"T220","span":{"begin":804,"end":886},"obj":"Sentence"},{"id":"T221","span":{"begin":887,"end":929},"obj":"Sentence"},{"id":"T222","span":{"begin":930,"end":998},"obj":"Sentence"},{"id":"T223","span":{"begin":999,"end":1070},"obj":"Sentence"},{"id":"T224","span":{"begin":1071,"end":1139},"obj":"Sentence"},{"id":"T225","span":{"begin":1140,"end":1211},"obj":"Sentence"},{"id":"T226","span":{"begin":1212,"end":1280},"obj":"Sentence"},{"id":"T227","span":{"begin":1281,"end":1353},"obj":"Sentence"},{"id":"T228","span":{"begin":1354,"end":1420},"obj":"Sentence"},{"id":"T229","span":{"begin":1421,"end":1489},"obj":"Sentence"},{"id":"T230","span":{"begin":1490,"end":1568},"obj":"Sentence"},{"id":"T231","span":{"begin":1569,"end":1641},"obj":"Sentence"},{"id":"T232","span":{"begin":1642,"end":1711},"obj":"Sentence"},{"id":"T233","span":{"begin":1712,"end":1787},"obj":"Sentence"},{"id":"T234","span":{"begin":1788,"end":1816},"obj":"Sentence"},{"id":"T235","span":{"begin":1817,"end":1824},"obj":"Sentence"},{"id":"T236","span":{"begin":1825,"end":1916},"obj":"Sentence"},{"id":"T237","span":{"begin":1917,"end":1960},"obj":"Sentence"},{"id":"T238","span":{"begin":1961,"end":2006},"obj":"Sentence"},{"id":"T239","span":{"begin":2007,"end":2051},"obj":"Sentence"},{"id":"T240","span":{"begin":2052,"end":2094},"obj":"Sentence"},{"id":"T241","span":{"begin":2095,"end":2140},"obj":"Sentence"},{"id":"T242","span":{"begin":2141,"end":2186},"obj":"Sentence"},{"id":"T243","span":{"begin":2187,"end":2372},"obj":"Sentence"},{"id":"T244","span":{"begin":2373,"end":2548},"obj":"Sentence"},{"id":"T245","span":{"begin":2549,"end":2580},"obj":"Sentence"},{"id":"T246","span":{"begin":2581,"end":2612},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T3","span":{"begin":186,"end":189},"obj":"GlycoEpitope"}],"attributes":[{"id":"A3","pred":"glyco_epitope_db_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/AN0690"}],"text":"The application of COVID-19 docking server and Discovery Studio software elucidated the interactions between the 20 lead-likeness compounds (S1, W5, MX17, MX16, W11, M5, XO1, MXO1, SO1, WO1, X4, MX8, M3, S5, SX1, O1, X2, X1, O2, MS1) and the 10 nonstructural and 2 structural proteins (Mpro, PLpro, nsp12 [RdRp with RNA], nsp12 [RdRp without RNA], nsp13 [Helicase ADP site], nsp13 [Helicase NCB site], nsp14 [ExoN], nsp14 [N7-MTase], nsp15 [endoribonuclease], nsp16 [2′-O-MTase], N protein NCB site, E protein [ion channel]). The docking scores were depicted in Table 3, Table 4 . The smaller of docking score, the lower of energy would be required, which means the binding between the compounds and the targets are stronger. There are 9 compounds presenting better bonding ability than other compounds.\nTable 3 Docking score between specific ingredients of QFPD and 2019-nCov proteins.\nMolecule M3 M5 S1 S5 W11 W5 X1 X2 X4 O1 O2\nMain Protease −7.7 −7.3 −6.8 −6.9 −7.2 −7.5 −7.1 −7.9 −7.3 −7.1 −7.4\nPapain-like protease −8.7 −8.5 −9.9 −7.7 −8 −8 −8.4 −8.7 −8.2 −8.6 −8.2\nRdRp with RNA −8.4 −8.5 −8.5 −8.3 −9.1 −9.1 −8.4 −8.2 −8.2 −8.3 −8.6\nRdRp without RNA −6.8 −6.8 −6.9 −6.8 −6.7 −6.9 −7.1 −7.2 −6.5 −7.3 −7.1\nHelicase ADP site −6.3 −6.3 −7.3 −6.5 −6 −6 −6.3 −6.5 −6.2 −6.1 −6.5\nHelicase NCB site −7.9 −6.9 −7.2 −7.1 −7.2 −7.2 −7.4 −7.5 −7.3 −7.4 −7.4\nNsp14(ExoN) −6.8 −6.6 −6.3 −6.4 −6.9 −6.8 −6.7 −6.9 −6.4 −6.6 −6.9\nNsp14(N7-MTase) −8.8 −8.1 −8.5 −7.5 −8.4 −8.4 −8.3 −8.5 −8 −8.3 −8.5\nNsp15(endoribonuclease) −6.6 −6.3 −6.3 −5.9 −6.2 −6.2 −6.2 −6.3 −6.2 −6.4 −6.4\nNsp16(2′-O-MTase) −7.5 −7.4 −7.5 −7.2 −8.2 −8.2 −7.7 −7.9 −7.7 −7.9 −8.4\nN protein NCB site −7.6 −7.5 −7.8 −7.6 −7.6 −7.6 −8 −8 −7.5 −7.6 −7.6\nE protein(ion channel) −8.1 −7 −7.8 −6.7 −6.4 −6.4 −7.2 −7.3 −7.2 −7.1 −6.8\nM: MXSG, S: SGMH, X: XCH, O: Others.\nTable 4 Evaluation of the effect of QFPD on the robustness disturbance of COVID-19 network.\nTopology MXSG SGMH XCH WLS Others BXTM YDBF\nDTS 25.66 26.71 21.02 17.64 23.16 14.52 22.71\nAC −4.63 −5.21 −3.02 −3.49 −5.38 −2.32 −3.78\nAPL 13.35 13.40 9.96 6.49 10.66 4.59 11.17\nCoC −1.44 −1.64 −1.59 −1.30 −1.23 −1.15 −1.25\nClC −6.24 −6.46 −6.45 −6.36 −5.88 −6.46 −6.52\nAverage connectivity (AC), Connection centrality (CoC), Closeness centrality (ClC): the larger the quotient is, the more stable the network and, the less the influence made by the drug. Disturbance total score (DTS), Average length of shortest path (APL), : the larger the quotient is, the less stable the network and, the larger the influence made by the drug. Negative control formula: BXTM. Positive control formula: YDBF."}